C-5-Disubstituted Barbiturates as Potential Molecular Probes for Noninvasive Matrix Metalloproteinase Imaging
- 12 April 2005
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (9) , 3400-3409
- https://doi.org/10.1021/jm049145x
Abstract
Studies have demonstrated a positive correlation between inflammation, metastasis, or atherosclerosis and the unbalanced or culminated expression of matrix metalloproteinases (MMPs). The molecular imaging of locally upregulated MMP activity in vivo is a clinical challenge. Actually, radioligands based on nonpeptidyl MMP inhibitors (MMPIs) are currently in development as putative radiopharmaceutical agents for the noninvasive in vivo assessment of activated MMPs. Nonpeptidyl MMPIs bind to the zinc active site of the activated enzyme via mono- (e.g. carboxylate) or bidentate (e.g. hydroxamate) complexation thereby exhibiting a broad-spectrum MMP binding potency. Thus, these mentioned endopeptidase inhibitors should be useable lead compounds for the redevelopment as diagnostic MMPI radiotracers. Recently, the non-hydroxamate C-5-disubstituted pyrimidine-2,4,6-triones were disclosed as subgroup-selective MMP inhibitors. We here describe a set of fine-tuned barbiturates as a new class of MMPI radiotracers for the noninvasive in vivo visualization of activated MMPs using scintigraphic techniques such as SPECT or PET.Keywords
This publication has 18 references indexed in Scilit:
- Anti-Invasive, Antitumoral, and Antiangiogenic Efficacy of a Pyrimidine-2,4,6-trione Derivative, an Orally Active and Selective Matrix Metalloproteinases InhibitorClinical Cancer Research, 2004
- Scintigraphic Imaging of Matrix Metalloproteinase Activity in the Arterial Wall In VivoCirculation, 2004
- Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivoNuclear Medicine and Biology, 2004
- Extracellular matrix remodelling: the role of matrix metalloproteinasesThe Journal of Pathology, 2003
- The dynamic extracellular matrix: intervention strategies during heart failure and atherosclerosisThe Journal of Pathology, 2003
- Design and synthesis of fluorine-18 labeled matrix metalloproteinase inhibitors for cancer imagingJournal of Labelled Compounds and Radiopharmaceuticals, 2002
- Strategies for MMP inhibition in cancer: innovations for the post-trial eraNature Reviews Cancer, 2002
- Matrix Metalloproteinase Inhibitors and Cancer—Trials and TribulationsScience, 2002
- X‐ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysinProtein Science, 2001
- Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in RabbitsJournal of Medicinal Chemistry, 1997